FYU-981, (Oral single dosing)

DRUG3 trials

Sponsors

Fuji Yakuhin Co., Ltd.

Conditions

HealthyRenal Insufficiency

Phase 1

Clinical Pharmacology of FYU-981 (Elder Subjects)

CompletedNCT02344875

Fuji Yakuhin Co., Ltd.Healthy

Start: 2014-05-31End: 2014-07-31Updated: 2015-01-26

Clinical Pharmacology of FYU-981 (Subjects With Renal Insufficiency)

CompletedNCT02347046

Fuji Yakuhin Co., Ltd.Healthy, Renal Insufficiency

Start: 2015-01-31End: 2015-03-31Updated: 2015-03-06

Single Dose Phase I Study of FYU-981

CompletedNCT02348307

Fuji Yakuhin Co., Ltd.Healthy

Start: 2013-03-31End: 2013-08-31Updated: 2015-01-28

Related Papers

Clinical pharmacological study of dotinurad administered to male and female elderly or young subjects.

2019-12-305 citations

Open-label study of long-term administration of dotinurad in Japanese hyperuricemic patients with or without gout.

2019-12-2622 citations

Effects of mild and moderate renal dysfunction on pharmacokinetics, pharmacodynamics, and safety of dotinurad: a novel selective urate reabsorption inhibitor.

2019-12-105 citations

Clinical efficacy and safety of dotinurad, a novel selective urate reabsorption inhibitor, in Japanese hyperuricemic patients with or without gout: randomized, multicenter, double-blind, placebo-controlled, parallel-group, confirmatory phase 2 study.

2019-12-0322 citations

Clinical efficacy and safety of dotinurad, a novel selective urate reabsorption inhibitor, in Japanese hyperuricemic patients with or without gout: an exploratory, randomized, multicenter, double-blind, placebo-controlled, parallel-group early phase 2 study

Clinical and Experimental Nephrology2019-11-2118 citations